Cipla Ltd.
CIPLAHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
32 transcript(s)/analyst meet(s) served; 1 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 32 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20190211 | 2018-12-31 | yes | |
| TRANSCRIPT | 20190528 | 2019-03-31 | yes | |
| TRANSCRIPT | 20190813 | 2019-06-30 | yes | |
| TRANSCRIPT | 20191112 | 2019-09-30 | yes | |
| TRANSCRIPT | 20200211 | 2019-12-31 | yes | |
| TRANSCRIPT | 20200519 | 2020-03-31 | yes | |
| TRANSCRIPT | 20200811 | 2020-06-30 | yes | |
| TRANSCRIPT | 20201110 | 2020-09-30 | yes | |
| TRANSCRIPT | 20210202 | 2020-12-31 | yes | |
| TRANSCRIPT | 20210518 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210810 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211031 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220129 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220517 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220802 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221108 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230130 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230516 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230729 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231031 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240129 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240515 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240729 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241102 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250131 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250516 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250728 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251103 | 2025-09-30 | yes | |
| COVER_LETTER | 20260109 | 2025-12-31 | no | |
| TRANSCRIPT | 20260127 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260515 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260727 | 2026-06-30 | yes |
CIPLA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,399.00 |
| 52-week range | 1192.4 – 1645.1 |
| Return 1M | -1.62% |
| Return 3M | -2.85% |
| Return 1Y | -9.04% |
| Return 3Y | 18.62% |
| Return 5Y | 44.58% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 7,119.00 |
| Other income | 211.00 |
| Total income | 7,330.00 |
| Cost of materials consumed | 1,357.00 |
| Purchases of stock-in-trade | 1,252.00 |
| Changes in inventories | 59.00 |
| Employee benefit expense | 1,497.00 |
| Finance costs | 17.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.29 | 0.00 |
| institutions foreign | 0.20 | -0.02 |
| institutions domestic | 0.35 | 0.03 |
| mutual funds | 0.21 | 0.02 |
| public | 0.71 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2025-12-31 | 1 |
| TRANSCRIPT | 2026-06-30 | 31 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 5,829.00 | 5,810.00 | 5,739.00 | 6,329.00 | 6,678.00 | 6,604.00 | 6,163.00 | 6,694.00 | 7,051.00 | 7,073.00 | 6,730.00 | 6,957.00 | 7,589.00 | 7,074.00 | 6,541.00 | 7,119.00 |
| Other income | 123.00 | 114.00 | 135.00 | 136.00 | 176.00 | 185.00 | 249.00 | 160.00 | 191.00 | 222.00 | 289.00 | 259.00 | 269.00 | 206.00 | 148.00 | 211.00 |
| Total income | 5,951.00 | 5,925.00 | 5,874.00 | 6,465.00 | 6,854.00 | 6,788.00 | 6,413.00 | 6,854.00 | 7,242.00 | 7,295.00 | 7,019.00 | 7,216.00 | 7,858.00 | 7,281.00 | 6,689.00 | 7,330.00 |
| Cost of materials consumed | 1,433.00 | 1,299.00 | 1,264.00 | 1,299.00 | 1,473.00 | 1,196.00 | 1,253.00 | 1,241.00 | 1,474.00 | 1,297.00 | 1,398.00 | 1,469.00 | 1,528.00 | 1,462.00 | 1,382.00 | 1,357.00 |
| Purchases of stock-in-trade | 682.00 | 712.00 | 782.00 | 980.00 | 890.00 | 927.00 | 739.00 | 1,100.00 | 815.00 | 913.00 | 1,024.00 | 1,025.00 | 893.00 | 1,249.00 | 1,285.00 | 1,252.00 |
| Changes in inventories | 45.00 | -6.00 | 17.00 | -42.00 | -50.00 | 96.00 | 58.00 | -148.00 | -6.00 | 54.00 | -233.00 | -324.00 | 76.00 | -79.00 | -418.00 | 59.00 |
| Employee benefit expense | 961.00 | 949.00 | 965.00 | 1,067.00 | 1,091.00 | 1,068.00 | 1,084.00 | 1,194.00 | 1,208.00 | 1,198.00 | 1,233.00 | 1,312.00 | 1,315.00 | 1,325.00 | 1,414.00 | 1,497.00 |
| Finance costs | 26.00 | 32.00 | 34.00 | 16.00 | 26.00 | 30.00 | 18.00 | 18.00 | 15.00 | 15.00 | 14.00 | 14.00 | 13.00 | 14.00 | 13.00 | 17.00 |
| Depreciation and amortisation | 299.00 | 272.00 | 346.00 | 239.00 | 290.00 | 233.00 | 288.00 | 247.00 | 272.00 | 280.00 | 309.00 | 253.00 | 297.00 | 278.00 | 383.00 | 304.00 |
| Other expenses | 1,405.00 | 1,450.00 | 1,537.00 | 1,532.00 | 1,540.00 | 1,569.00 | 1,713.00 | 1,591.00 | 1,675.00 | 1,622.00 | 1,770.00 | 1,696.00 | 1,882.00 | 1,862.00 | 1,923.00 | 1,762.00 |
| Total expenses | 4,851.00 | 4,706.00 | 4,946.00 | 5,091.00 | 5,260.00 | 5,120.00 | 5,153.00 | 5,243.00 | 5,453.00 | 5,378.00 | 5,515.00 | 5,446.00 | 6,005.00 | 6,112.00 | 5,982.00 | 6,248.00 |
| Profit before exceptional items and tax | 1,100.00 | 1,218.00 | 928.00 | 1,375.00 | 1,594.00 | 1,669.00 | 1,259.00 | 1,611.00 | 1,789.00 | 1,916.00 | 1,504.00 | 1,770.00 | 1,854.00 | 1,169.00 | 707.00 | 1,082.00 |
| Exceptional items | 0.00 | 0.00 | -182.00 | 0.00 | 0.00 | -195.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -276.00 | 0.00 | 0.00 |
| Profit before tax | 1,100.00 | 1,218.00 | 745.00 | 1,375.00 | 1,594.00 | 1,474.00 | 1,259.00 | 1,611.00 | 1,789.00 | 1,916.00 | 1,504.00 | 1,770.00 | 1,854.00 | 893.00 | 707.00 | 1,082.00 |
| Current tax | 335.00 | 313.00 | 317.00 | 399.00 | 457.00 | 330.00 | 511.00 | 431.00 | 459.00 | 338.00 | 480.00 | 530.00 | 468.00 | 161.00 | 282.00 | 393.00 |
| Deferred tax | -33.00 | 97.00 | -95.00 | -21.00 | -18.00 | 76.00 | -186.00 | 4.00 | 24.00 | -5.00 | -201.00 | -52.00 | 32.00 | 58.00 | -125.00 | -98.00 |
| Tax expense | 303.00 | 410.00 | 222.00 | 378.00 | 438.00 | 405.00 | 325.00 | 435.00 | 483.00 | 332.00 | 279.00 | 478.00 | 500.00 | 219.00 | 157.00 | 295.00 |
| Profit for the period | 797.00 | 808.00 | 522.00 | 998.00 | 1,155.00 | 1,068.00 | 932.00 | 1,175.00 | 1,305.00 | 1,575.00 | 1,214.00 | 1,292.00 | 1,353.00 | 674.00 | 543.00 | 786.00 |
| Profit attributable to owners | 789.00 | 801.00 | 526.00 | 996.00 | 1,131.00 | 1,056.00 | 939.00 | 1,178.00 | 1,303.00 | 1,571.00 | 1,222.00 | 1,298.00 | 1,351.00 | 676.00 | 555.00 | 789.00 |
| Profit attributable to non-controlling interests | 9.00 | 7.00 | -4.00 | 2.00 | 24.00 | 13.00 | -7.00 | -2.00 | 2.00 | 4.00 | -8.00 | -6.00 | 2.00 | -2.00 | -12.00 | -4.00 |
| Other comprehensive income | -43.00 | 252.00 | -69.00 | -108.00 | 64.00 | 2.00 | -79.00 | 71.00 | 131.00 | -38.00 | 54.00 | 81.00 | 266.00 | 204.00 | 136.00 | 194.00 |
| Total comprehensive income | 755.00 | 1,060.00 | 453.00 | 890.00 | 1,220.00 | 1,071.00 | 852.00 | 1,246.00 | 1,436.00 | 1,537.00 | 1,269.00 | 1,373.00 | 1,620.00 | 878.00 | 678.00 | 980.00 |
| Earnings per share, basic | 9.78 | 9.92 | 6.51 | 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.07 | 16.73 | 8.37 | 6.87 | 9.77 |
| Earnings per share, diluted | 9.77 | 9.92 | 6.51 | 12.33 | 14.00 | 13.07 | 11.62 | 14.57 | 16.12 | 19.43 | 15.12 | 16.06 | 16.72 | 8.36 | 6.86 | 9.76 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 16,362.00 | 17,132.00 | 19,160.00 | 21,763.00 | 22,753.00 | 25,774.00 | 27,548.00 | 28,163.00 |
| Other income | 477.00 | 344.00 | 266.00 | 281.00 | 475.00 | 747.00 | 862.00 | 882.00 |
| Total income | 16,839.00 | 17,476.00 | 19,426.00 | 22,044.00 | 23,229.00 | 26,521.00 | 28,409.00 | 29,045.00 |
| Cost of materials consumed | 4,285.00 | 4,377.00 | 4,886.00 | 5,533.00 | 5,520.00 | 5,221.00 | 5,410.00 | 5,842.00 |
| Purchases of stock-in-trade | 1,452.00 | 1,859.00 | 2,658.00 | 3,687.00 | 2,829.00 | 3,536.00 | 3,851.00 | 4,451.00 |
| Changes in inventories | 47.00 | -245.00 | -193.00 | -725.00 | -96.00 | 63.00 | -332.00 | -744.00 |
| Employee benefit expense | 2,857.00 | 3,027.00 | 3,252.00 | 3,530.00 | 3,830.00 | 4,310.00 | 4,833.00 | 5,366.00 |
| Finance costs | 168.00 | 197.00 | 161.00 | 106.00 | 110.00 | 90.00 | 62.00 | 54.00 |
| Depreciation and amortisation | 1,326.00 | 1,175.00 | 1,068.00 | 1,052.00 | 1,172.00 | 1,051.00 | 1,107.00 | 1,211.00 |
| Other expenses | 4,624.00 | 4,908.00 | 4,303.00 | 5,185.00 | 5,644.00 | 6,353.00 | 6,658.00 | 7,364.00 |
| Total expenses | 14,760.00 | 15,298.00 | 16,136.00 | 18,369.00 | 19,008.00 | 20,624.00 | 21,589.00 | 23,545.00 |
| Profit before exceptional items and tax | 2,079.00 | 2,178.00 | 3,290.00 | 3,675.00 | 4,221.00 | 5,897.00 | 6,821.00 | 5,500.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | -182.00 | -182.00 | -195.00 | 0.00 | -276.00 |
| Profit before tax | 2,079.00 | 2,178.00 | 3,290.00 | 3,493.00 | 4,038.00 | 5,702.00 | 6,821.00 | 5,224.00 |
| Current tax | 748.00 | 683.00 | 1,053.00 | 1,137.00 | 1,265.00 | 1,697.00 | 1,708.00 | 1,441.00 |
| Deferred tax | -178.00 | -52.00 | -164.00 | -203.00 | -62.00 | -150.00 | -179.00 | -87.00 |
| Tax expense | 570.00 | 631.00 | 889.00 | 934.00 | 1,203.00 | 1,547.00 | 1,530.00 | 1,354.00 |
| Profit for the period | 1,492.00 | 1,500.00 | 2,389.00 | 2,547.00 | 2,833.00 | 4,154.00 | 5,269.00 | 3,862.00 |
| Profit attributable to owners | 1,528.00 | 1,547.00 | 2,405.00 | 2,517.00 | 2,802.00 | 4,122.00 | 5,273.00 | 3,879.00 |
| Profit attributable to non-controlling interests | -35.00 | -47.00 | -16.00 | 30.00 | 31.00 | 32.00 | -3.00 | -17.00 |
| Other comprehensive income | -290.00 | -129.00 | 161.00 | 384.00 | 138.00 | -121.00 | 219.00 | 688.00 |
| Total comprehensive income | 1,202.00 | 1,370.00 | 2,550.00 | 2,930.00 | 2,971.00 | 4,033.00 | 5,488.00 | 4,549.00 |
| Earnings per share, basic | 18.97 | 19.19 | 29.82 | 31.20 | 34.72 | 51.05 | 65.29 | 48.03 |
| Earnings per share, diluted | 18.93 | 19.16 | 29.79 | 31.17 | 34.69 | 51.01 | 65.24 | 48.00 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 28,063.00 | 29,463.00 | 31,377.00 | 32,718.00 | 34,655.00 | 37,387.00 | 40,164.00 | 42,496.00 |
| Non-current assets | 12,157.00 | 12,188.00 | 12,370.00 | 13,276.00 | 13,710.00 | 14,099.00 | 15,244.00 | 18,349.00 |
| Current assets | 15,889.00 | 16,805.00 | 18,468.00 | 19,392.00 | 20,906.00 | 23,249.00 | 24,918.00 | 24,146.00 |
| Property, plant and equipment | 5,080.00 | 4,991.00 | 4,819.00 | 5,069.00 | 5,119.00 | 5,262.00 | 5,503.00 | 6,040.00 |
| Capital work-in-progress | 510.00 | 689.00 | 791.00 | 864.00 | 1,097.00 | 1,213.00 | 1,437.00 | 1,586.00 |
| Goodwill | 3,143.00 | 2,984.00 | 2,966.00 | 3,112.00 | 3,251.00 | 3,270.00 | 3,451.00 | 3,754.00 |
| Other intangible assets | 1,164.00 | 1,126.00 | 1,111.00 | 1,313.00 | 1,570.00 | 1,363.00 | 1,454.00 | 2,640.00 |
| Inventories | 5,441.00 | 5,156.00 | 5,470.00 | 5,238.00 | 5,573.00 | 5,642.00 | 6,160.00 | 6,597.00 |
| Trade receivables | 3,969.00 | 4,057.00 | 4,850.00 | 4,771.00 | 5,588.00 | 5,506.00 | 6,902.00 | 5,620.00 |
| Cash and cash equivalents | 687.00 | 628.00 | 800.00 | 640.00 | 798.00 | 589.00 | 762.00 | 1,018.00 |
| Total equity and liabilities | 28,063.00 | 29,463.00 | 31,377.00 | 32,718.00 | 34,655.00 | 37,387.00 | 40,164.00 | 42,496.00 |
| Equity | 22,169.00 | 23,714.00 | 25,095.00 | 26,802.00 | 28,456.00 | 31,289.00 | 33,025.00 | 34,520.00 |
| Equity share capital | 161.00 | 161.00 | 161.00 | 161.00 | 162.00 | 162.00 | 162.00 | 162.00 |
| Other equity | 21,723.00 | 23,246.00 | 24,664.00 | 26,545.00 | 28,201.00 | 31,032.00 | 32,757.00 | 34,270.00 |
| Total liabilities | 5,893.00 | 5,750.00 | 6,282.00 | 5,915.00 | 6,200.00 | 6,098.00 | 7,139.00 | 7,976.00 |
| Non-current liabilities | 584.00 | 640.00 | 633.00 | 670.00 | 745.00 | 614.00 | 842.00 | 962.00 |
| Current liabilities | 5,309.00 | 5,033.00 | 5,559.00 | 5,246.00 | 5,455.00 | 5,484.00 | 6,297.00 | 7,014.00 |
| Borrowings, non-current | 12.00 | 0.00 | 0.00 | 0.00 | 10.00 | 12.00 | 18.00 | 117.00 |
| Borrowings, current | 841.00 | 520.00 | 674.00 | 247.00 | 152.00 | 80.00 | 76.00 | 140.00 |
| Trade payables | 2,401.00 | 2,457.00 | 2,675.00 | 2,474.00 | 2,675.00 | 2,837.00 | 3,035.00 | 3,230.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 1,134.00 | 3,238.00 | 1,689.00 | 4,134.00 | 2,055.00 | 5,005.00 | 1,345.00 | 3,940.00 |
| Net cash from investing activities | -620.00 | -2,389.00 | -742.00 | -2,988.00 | -710.00 | -3,691.00 | 159.00 | -2,326.00 |
| Net cash from financing activities | -517.00 | -958.00 | -708.00 | -1,200.00 | -1,183.00 | -1,293.00 | -1,318.00 | -1,234.00 |
| Purchase of property, plant and equipment | 392.00 | 841.00 | 486.00 | 1,098.00 | 626.00 | 1,162.00 | 665.00 | 1,599.00 |
| Net increase in cash | -31.00 | -97.00 | 238.00 | -49.00 | 178.00 | 30.00 | 203.00 | 473.00 |
| con:CFO.BEFORE_TAX | 1,606.00 | 4,540.00 | 2,351.00 | 5,731.00 | 2,633.00 | 6,673.00 | 2,108.00 | 5,526.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 473.00 | 1,302.00 | 662.00 | 1,597.00 | 578.00 | 1,668.00 | 762.00 | 1,586.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 51.00 | 187.00 | 4.00 | 42.00 | 15.00 | 31.00 | 16.00 | 16.00 |
| con:INVESTMENTS_SOLD | 0.00 | 26.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 3.00 | 30.00 | 8.00 | 34.00 | 8.00 | 25.00 | 15.00 | 24.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 50.00 | 120.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 301.00 | 130.00 | 205.00 | 0.00 | 111.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 33.55 | 33.47 | 33.47 | 33.47 | 33.47 | 30.91 | 30.92 | 29.19 | 29.20 | 0.29 | 0.29 | 0.29 | 0.29 | 0.29 |
| Domestic institutions | 22.10 | 24.34 | 24.18 | 24.33 | 24.42 | 24.95 | 24.16 | 27.71 | 28.15 | 0.29 | 0.30 | 0.31 | 0.32 | 0.35 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 0.20 | 0.20 | 0.19 | 0.19 | 0.21 |
| Insurance companies | 4.74 | 6.26 | 5.25 | 5.34 | 5.44 | 5.18 | 4.67 | 5.10 | 5.79 | 0.07 | 0.08 | 0.10 | 0.11 | 0.12 |
| Foreign institutions | 27.42 | 25.49 | 25.74 | 25.73 | 25.83 | 27.81 | 28.80 | 26.65 | 26.28 | 0.25 | 0.25 | 0.24 | 0.23 | 0.20 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 66.45 | 66.53 | 66.53 | 66.53 | 66.53 | 69.09 | 69.08 | 70.81 | 70.80 | 0.71 | 0.71 | 0.71 | 0.71 | 0.71 |
| Non-institutional | 16.94 | 16.69 | 16.60 | 16.46 | 16.28 | 16.33 | 16.11 | 16.44 | 16.37 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 |
| Shares outstanding | 803745869 | 805582040 | 805629927 | 805654896 | 805671560 | 806204667 | 805858494 | 806012318 | 805876472 | 805983014 | 805388182 | 805375803 | 805382462 | 805418551 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Cipla USA Inc. | Holding-Subsidiary | Any other transaction, Interest received, Loan, Purc | 27,049,000,000.00 | 17 |
| Cipla Pharma and Life Sciences Limited | Holding-Subsidiary | Any other transaction, Interest received, Loan, Purc | 3,479,400,000.00 | 11 |
| Medpro Pharmaceutica (Pty) Limited | Subsidiaries | Any other transaction, Loan, Sale of goods or servic | 3,479,000,000.00 | 14 |
| Cipla Health Limited | Holding-Subsidiary | Any other transaction, Interest received, Loan, Purc | 2,979,500,000.00 | 13 |
| Cipla (EU) Limited | Holding-Subsidiary | Any other transaction, Investment, Purchase of goods | 2,503,800,000.00 | 9 |
| Medispray Laboratories Private Limited | Holding-Subsidiary | Any other transaction, Purchase of goods or services | 2,413,800,000.00 | 13 |
| Medpro Pharamaceutica (Pty) Limited | Holding-Subsidiary | Any other transaction, Sale of goods or services | 2,369,800,000.00 | 5 |
| Exelan Pharmaceuticals Inc. | Holding-Subsidiary | Any other transaction, Sale of goods or services | 1,932,100,000.00 | 8 |
| Cipla Pharmaceuticals Limited | Holding-Subsidiary | Any other transaction, Investment, Sale of goods or | 1,302,200,000.00 | 6 |
| Societe Marocaine De Cooperation Pharmaceutique (Cooper) | Related party of a subsidiary | Any other transaction, Purchase of goods or services | 1,157,600,000.00 | 6 |
| Goldencross Pharma Limited | Holding-Subsidiary | Any other transaction, Purchase of fixed assets, Pur | 1,034,100,000.00 | 7 |
| Cipla Limited Employees Gratuity Fund | Post Employment Benefit Trust | Any other transaction | 1,000,000,000.00 | 2 |
| Sitec Labs Limited | Holding-Subsidiary | Any other transaction, Interest received, Loan, Sale | 830,400,000.00 | 10 |
| Jay Precision Pharmaceuticals Private Limited | Holding-Subsidiary | Any other transaction, Purchase of goods or services | 764,100,000.00 | 2 |
| Cipla Medpro South Africa (Pty) Limited | Holding-Subsidiary | Any other transaction, Interest received, Loan | 710,900,000.00 | 5 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-27 | Q1FY27 | Read the call | |
| 2026-05-15 | Q4FY26 | Read the call | |
| 2026-01-27 | Q3FY26 | Read the call | |
| 2025-11-03 | Q2FY26 | OFFICER – CIPLA LIMITED, RELATIONS– CIPLA LIMITED | Read the call |
| 2025-07-28 | Q1FY26 | Read the call | |
| 2025-05-16 | Q4FY25 | OFFICER – CIPLA LIMITED, RELATIONS – CIPLA LIMITED | Read the call |
| 2025-01-31 | Q3FY25 | LIMITED | Read the call |
| 2024-11-02 | Q2FY25 | LIMITED | Read the call |
| 2024-07-29 | Q1FY25 | Read the call | |
| 2024-05-15 | Q4FY24 | OFFICER – CIPLA LIMITED, RELATIONS – CIPLA LIMITED | Read the call |
| 2024-01-29 | Q3FY24 | OFFICER – CIPLA LIMITED, RELATIONS – CIPLA LIMITED | Read the call |
| 2023-10-31 | Q2FY24 | RELATIONS), CIPLA LIMITED | Read the call |
| 2023-07-29 | Q1FY24 | Read the call | |
| 2023-05-16 | Q4FY23 | Read the call | |
| 2023-01-30 | Q3FY23 | LIMITED, OFFICER – CIPLA LIMITED | Read the call |
| 2022-11-08 | Q2FY23 | CIPLA LIMITED, OFFICER, CIPLA LIMITED | Read the call |
| 2022-08-02 | Q1FY23 | Cipla, FINANCIAL OFFICER, CIPLA LIMITED | Read the call |
| 2022-05-17 | Q4FY22 | GLOBAL CEO, CIPLA LIMITED, LIMITED | Read the call |
| 2022-01-29 | Q3FY22 | GLOBAL CEO, CIPLA LTD. | Read the call |
| 2021-10-31 | Q2FY22 | CIPLA LIMITED, OFFICER, CIPLA LIMITED | Read the call |
| 2021-08-10 | Q1FY22 | Read the call | |
| 2021-05-18 | Q4FY21 | LIMITED | Read the call |
| 2021-02-02 | Q3FY21 | CIPLA LIMITED, LIMITED | Read the call |
| 2020-11-10 | Q2FY21 | CIPLA, EXECUTIVE, GLOBAL, SECURITIES | Read the call |
| 2020-08-11 | Q1FY21 | GLOBAL CEO, CIPLA LIMITED, LIMITED | Read the call |
| 2020-05-19 | Q4FY20 | GLOBAL CEO, CIPLA LIMITED, LIMITED | Read the call |
| 2020-02-11 | Q3FY20 | GLOBAL CEO, CIPLA LIMITED, LIMITED | Read the call |
| 2019-11-12 | Q2FY20 | LIMITED | Read the call |
| 2019-08-13 | Q1FY20 | CIPLA LIMITED, OFFICER - CIPLA LIMITED | Read the call |
| 2019-05-28 | Q4FY19 | LIMITED | Read the call |
| 2019-02-11 | Q3FY19 | CIPLA LIMITED, LIMITED | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q4FY19 | Q4FY20 | Q4FY21 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | This is for inorganic initiatives and other capital expenditure requirements. | And there are opportunities to deploy in the business both for our branded business and organic capex. | — | The first would be to support our CapEx program and to buy some assets in India where we can acquire. | And would you be sharing what would be the expense related to that, capex. | — | Sir, second question is about the capex for FY '26. | Then we have capex, which we have increased steadily over the last 3 years. |
| Capital allocation | And in Invagen as well, is there a plan to kind of divest these 2 parts? | — | — | Now currently it largely pertains to Invagen acquisition or there is more subparts to it? | Profit after tax for the quarter is at INR526 crores or 9.2% of sales, adjusting for onetime impairment charge on account of divestment of certain non… | In Cipla Health, Cipla Limited May 10, 2024 we entered into a brand acquisition for the cosmetic and personal care business of Ivia Beaute Private Lim… | And you would have seen that we have also accordingly maintained the dividend that we had increased in the last 2 years. | We had a small acquisition of a business called Inzpera. |
| Costs | — | — | One, pertaining to the increasing cost of raw materials that has been in the news for quite some time. | Continued focus on cost management, especially amid the inflationary environment we are, which is impacting our procurement costs and others. | So given all those things and plus, if you look at the material cost because of further inflation that we've seen in the last year, we have, of course… | Expansion and profitability is largely due to favorable mix, calibrated price actions across branded and generic portfolio and impact of easing cost i… | — | My question was more from a sourcing standpoint, the key raw materials that come from Europe, would they be cheaper for you? |
| Debt and cash | I think this year our total cash flow spend is below 500 crores. | Second, on the India business, leaving aside the impact that we saw in March and April in terms of inventory, do you think there is scope for further … | — | We had working capital loans of $49 million and EUR2 million. | Our free cash flow generation and operating efficiency continue to drive our healthy net cash position. | Free cash generation and operating efficiencies has resulted in a healthy cash position, as at the end of the year, the gross debt on our balance shee… | — | — |
| Demand | I mean, most bigger companies, smaller companies, we see they are taking 1 inventory correction in the last 7 quarters post the GST, so what is the se… | I am not sure we are at a point where we can tell you where demand will be because there are multiple moving parts on what is a red district, what is … | Other question is regarding again on the US Generics pipeline. | As alluded earlier, there is an approximate 300 basis point impact due to change in material cost line, largely pertaining to demand uncertainties lin… | We also continue to invest capital across multiple growth initiatives, including investments in the complex pipeline in new science into our big brand… | To make this journey sustainable, we are continuing our investments across the complex pipeline, the CapEx, the big brands and the operations. | To elevate our offerings, we will be launching innovative products like inhaled insulin and plazomicin backed by -- and are backed by a good pipeline … | And if you could update on the respiratory pipeline, the key assets, Advair, Symbicort, Qvar, Flovent? |
| Guidance | So, the other way, if you can help me understand on the base of $120 million, $125 million and given the pipe that we are expecting for 20, how do we … | And similarly the US market, at least half of the patients not able to go and get treated, so what is the outlook for the volume front. | We aren’t providing sector guidance Saion; so there will be growth in US and there will be a reasonable number of launches. | As we mitigate these challenges over the next 3 to 4 months, we expect the business trajectory to improve given the upcoming complex launches expected… | Our India consumer franchise is already tracking at INR1,000 crores plus on an annual basis, and we expect the EBITDA margin to move closer to mid-tee… | We expect to start supplies of the respules to U.S. from China a strong amount in the second half of FY '25. | The EBITDA margin stood at 22.8% for the quarter, higher by 150 basis points Y-o-Y and 25.9% for the year, marginally exceeding our guidance which was… | My first question is on the U.S. revenue guidance, what you are talking about, about $1 billion by the end of this year. |
| Margin | A) We are not starting off a high base, and the TLE, TEE prices have moved significantly South, but we will only play the market for products where we… | It could have been unusually high, but how do you explain the EBITDA margin coming down because this is kind of getting normalized is what I understan… | So I would have assumed that the gross margin would have improved. | Our company recorded the highest revenue and achieved several major milestones in our One-India and U.S. business, pivoting the business on an acceler… | In fiscal year '23, we recorded the highest ever revenue and EBITDA, including several major milestones in our One India and U.S. businesses, pivoting… | In FY '24, we recorded our highest ever revenue and EBITDA, including major milestones across our flagship businesses of One-India, North America and … | This performance was led by expansion across both DTM and B2B categories alongside consistent margin, stability and internal pipeline assets. | And my last question is on your gross margin trends. |
| People | — | A) What is your current capacity utilization? | — | — | — | — | — | — |
| Pricing | Now that the South Africa tender business has been rebased or the CGA has been rebased, when should we see the impact of the TLE and TLD and private m… | But even without it, this is a 60 million unit market with fairly attractive pricing even today. | All these details, Saion, we would be more comfortable to announce once the actual launch happens… the launch by the way is not far away from today, b… | And to some extent, you would try and offset this through levers available to a company through pricing, et cetera. | We do not expect the NLEM pricing impact to influence our growth significantly as it will be balanced via allowed price increases and continued volume… | But is there any risk that one should think about the pricing situation? | So companies were given pricing adjustments, which was at inflation then. | So when we already mentioned that we have around 22% kind of -- or more than 20% kind of market share in the Albuterol market itself in the U.S. So no… |
| Revenue growth | Shyam, we wouldn't want to be specific on normalized EBITDA margin, but I think every year between the revenue growth, cost improvements and productiv… | Let us say in India we see a good growth of 12%, 13% this quarter itself. | — | 5,260 crore, recording a year-on-your growth of 14%. | Our India branded prescription business delivered sustained momentum across all our therapies, achieving 13% excluding COVID year-on-year growth while… | Our One-India business posted a healthy growth of 10% for this year, propelled by traction in the Branded Prescription and Trade Generics, while Consu… | Our One India business posted a healthy growth of 8% year- on-year this quarter with a full year growth of 7% year-on-year, driven by substantial prog… | So every year, we take some target to actually reduce the cost such that it is lesser than the revenue growth that you see out there. |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-08-02 | Q1FY23 | Cipla | Cipla Limited July 29, 2022 profitability for the quarter came in at 21.3% which is tracking in line with the full year 21%- 22% range, we guided to earlier. |
| 2022-08-02 | Q1FY23 | Cipla | The 21.3% tracks closely to the guidance of the 21%-22% range for the full year 2023. |
| 2022-08-02 | Q1FY23 | Cipla | Cipla Limited July 29, 2022 • Our international market business continues to grow despite ongoing geopolitical volatility and • Our reported EBITDA margin of 21.3% with the elevated cost base baked in, tracks closely with our guidance of 21%-22% for the full year. |
| 2022-11-08 | Q2FY23 | CIPLA LIMITED | At the current run rate, we are tracking in line with our full year guidance of 21% to about 22%. |
| 2022-11-08 | Q2FY23 | CIPLA LIMITED | We are tracking to our earlier guidance of reaching 15%-odd percent market share by the end of this year in this category. |